Simplification of Care for Chronic Hepatitis C Virus Infection

Author:

Pawlotsky Jean-Michel1,Ramers Christian B.2,Dillon John F.3,Feld Jordan J.4,Lazarus Jeffrey V.5

Affiliation:

1. Department of Virology, National Reference Center for Viral Hepatitis B, C and D, Henri Mondor Hospital, University of Paris-Est—INSERM U955, Créteil, France

2. Division of Infectious Diseases, Department of Medicine, UC San Diego School of Medicine, La Jolla, California

3. Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom

4. Toronto Centre for Liver Disease, University Health Network, Sandra Rotman Centre for Global Health, Toronto, ON, Canada

5. Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain

Abstract

AbstractIn 2016, the World Health Organization (WHO) set a target for eliminating viral hepatitis as a major public health threat by 2030. However, while today's highly effective and well-tolerated pangenotypic direct-acting antiviral regimens have maximized simplification of hepatitis C virus (HCV) treatment, there remain a plethora of barriers to HCV screening, diagnosis, and linkage to care. As of 2017, only 19% of the estimated 71 million individuals living with chronic HCV worldwide were diagnosed and in 2015 to 2016, only 21% of diagnosed individuals had accessed treatment. Simplification and decentralization of the HCV care cascade would bolster patient engagement and support the considerable scale-up needed to achieve WHO targets. Recent developments in HCV screening and diagnosis, together with reduced pretreatment assessment and on-treatment monitoring requirements, can further streamline the care continuum, ensuring patients are linked to care quickly and earlier in the disease course, and minimize clinic visits.

Funder

AbbVie

Publisher

Georg Thieme Verlag KG

Subject

Hepatology

Reference72 articles.

1. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission;G S Cooke;Lancet Gastroenterol Hepatol,2019

2. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade;J V Lazarus;J Intern Med,2019

3. EASL recommendations on treatment of hepatitis C 2018;European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver;J Hepatol,2018

4. CDC recommendations for hepatitis C screening among adults - United States, 2020;S Schillie;MMWR Recomm Rep,2020

5. EASL Clinical Practice Guidelines: management of hepatitis C virus infection;European Association for the Study of the Liver;J Hepatol,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3